, Clin Pharmacol Ther. Epub, 2019.

E. J. Smolders, A. Jansen, and P. Horst, Viral hepatitis C therapy: Pharmacokinetic and pharmacodynamic considerations: A 2019 update, Clin Pharmacokinet, 2019.

, European Medicines Agency. Epclusa® Summary of product characteristics, issue.8, 2019.

, European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018, J Hepatol, vol.69, pp.461-511, 2018.

, Association française pour l'étude du foie (AFEF), 2019.

, European Medicines Agency. Sovaldi® Summary of product characteristics, 2019.

E. Mogalian, P. German, and B. P. Kearney, Preclinical pharmacokinetics and first-inhuman pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects, Antimicrob Agents Chemother, vol.61, pp.2084-2100, 2017.